Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial-Reference-Cited by-同舟云学术

Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial

Published:2014-07-01 Issue: Volume: Page:n/a-n/a
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Chapple Christopher¹,Schneider Tim²,Haab François³,Sun Franklin⁴,Whelan Laurence⁵,Scholfield David⁵,Dragon Erika⁶,Mangan Erin⁴

Affiliation:

1. The Royal Hallamshire Hospital; Sheffield UK

2. Praxisklinik Urologie Rhein/Ruhr; Mülheim Germany

3. Hôpital Tenon; Paris France

4. Pfizer Inc.; New York NY USA

5. Pfizer Ltd; Walton Oaks UK

6. Pfizer PIO; Paris France

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.12678/fullpdf

Reference26 articles.

1. The economic impact of overactive bladder syndrome in six Western countries;Irwin;BJU Int,2009

2. The current and future burden and cost of overactive bladder in five European countries;Reeves;Eur Urol,2006

3. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome;Michel;Expert Opin Pharmacother,2008

4. The design and development of fesoterodine as a prodrug of 5- hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine;Malhotra;Curr Med Chem,2009

5. Understanding dose titration: overactive bladder treatment with fesoterodine as an example;Michel;Eur Urol Suppl,2011

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis;International braz j urol;2023-10

2. Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review;European Geriatric Medicine;2023-05-28

3. Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults;Cochrane Database of Systematic Reviews;2023-05-09

4. Effect of Pharmacotherapy for Overactive Bladder on the Incidence of and Factors Related to Urinary Tract Infection: A Systematic Review and Meta-analysis;Journal of Urology;2023-04

5. Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders;Pharmacological Reviews;2023-03-14